Summit Therapeutics (SMMT) Q3 2024 Earnings
SMMT·Reported October 30, 2024·Before market open
Diluted EPS came in at $-0.08, missed the $-0.07 consensus by $0.01.
Diluted EPS
$-0.08missed by $0.01
Consensus: $-0.07
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Summit Therapeutics's Q3 2024 earnings report.
Summit Therapeutics (SMMT) reported Q3 2024 earnings on October 30, 2024 before market open.
Summit Therapeutics reported diluted EPS of $-0.08 for Q3 2024.
EPS missed the consensus estimate of $-0.07 by $0.01.
You can read the 10-Q periodic report (0001599298-24-000158) directly on SEC EDGAR. The filing index links above go to sec.gov.